Advertisement

Topics

Nobody would buy Teva because of its debt

17:10 EDT 6 Aug 2017 | Globes

Pharmaceutical rivals will to try to exploit Teva's weakness and buy activities from it that are profitable, writes Omri Cohen.

Original Article: Nobody would buy Teva because of its debt

NEXT ARTICLE

More From BioPortfolio on "Nobody would buy Teva because of its debt"

Quick Search
Advertisement
 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...